Biomimetic dual-catalytic nanozyme remodels the liver fibrotic microenvironment to alleviate fibrosis
Regenerative Biomaterials · 22.01.2026 · 13
DOI: 10.1093/rb/rbag163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Regenerative Biomaterials, online erschienen am 03.11.2026. Verfasst von Xueyao Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu 610031, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Third People’s Hospital of Chengdu Clinical Research, Regional Innovation Cooperation Project of Sichuan Province, Third People’s Hospital of Chengdu Scientific Research Project.
Abstract (Originalsprache)
Activated hepatic stellate cells (HSCs) are the primary drivers of pathological extracellular matrix accumulation in liver fibrosis. Thus, inhibiting HSC activation is crucial for treatment; however, therapeutic efficacy often falls short of expectations. A major obstacle is the hypoxic, reactive oxygen species (ROS)-rich microenvironment, which fuels persistent HSC activation and compromises long-term treatment success. Here, we developed an activated HSC-targeted biomimetic nanozyme, HSC-HMMDN, by coating hollow mesoporous manganese dioxide nanoparticles (HMMDN) with membranes derived from activated HSCs to synergistically clear ROS and alleviate hypoxia. This homologous coating strategy enables precise recognition of surface adhesion molecules (such as integrins and N-cadherin) that are highly expressed on activated HSCs, ensuring targeted delivery. Once there, the nanozyme, endowed with superoxide dismutase- and catalase-like activities, scavenges excessive ROS, revives mitochondrial function and suppresses the TGF-β/Smad cascade to inhibit HSC activation. In a carbon tetrachloride (CCl4)-induced liver fibrosis rat model, HSC-HMMDN significantly ameliorated fibrosis and alleviated the hypoxic microenvironment without showing detectable toxicity. Overall, this targeted microenvironment remodeling strategy provides a new avenue for liver fibrosis therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu 610031, China.
- School of Medical Imaging, North Sichuan Medical College, Nanchong 637000, China.
- College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
- Department of Ultrasound, Huili People's Hospital, Liangshan 615100, China.
ORCID-Profile: Juying Zhang
Förderung
- Third People’s Hospital of Chengdu Clinical Research
- Regional Innovation Cooperation Project of Sichuan Province
- Third People’s Hospital of Chengdu Scientific Research Project
- the National Natural Science Foundation of China
Zitieren
APA
Tang, X., Zhang, J., Zhang, J., Huang, L., Li, C., Zhou, H., Ye, M., Du, J., Liu, Y., Zhou, Y., & Liu, Y. (2026). Biomimetic dual-catalytic nanozyme remodels the liver fibrotic microenvironment to alleviate fibrosis. Regenerative Biomaterials, 13. https://doi.org/10.1093/rb/rbag163
Vancouver
Tang X, Zhang J, Zhang J, Huang L, Li C, Zhou H, et al. Biomimetic dual-catalytic nanozyme remodels the liver fibrotic microenvironment to alleviate fibrosis. Regenerative Biomaterials. 2026;13. doi:10.1093/rb/rbag163
BibTeX
@article{Tang2026,
author = {Tang, Xueyao and Zhang, Juying and Zhang, Jixuan and Huang, Lei and Li, Changbao and Zhou, Hong and Ye, Ming and Du, Jujie and Liu, Yang and Zhou, Yang and Liu, Ying},
title = {Biomimetic dual-catalytic nanozyme remodels the liver fibrotic microenvironment to alleviate fibrosis},
journal = {Regenerative Biomaterials},
year = {2026},
volume = {13},
doi = {10.1093/rb/rbag163}
}
EUVIMED